SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive analyst upgrade that highlights the company's progress in regulatory pathways and validates the therapeutic potential of its lead candidate, Sonelokimab. Investors are actively discussing the stock's significant long-term growth prospects, the potential for a strategic buyout, and the upcoming clinical data readouts that are expected to solidify the drug's position as a best-in-class treatment.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is facing intense volatility as shareholders grapple with the end of a major lock-up period and skepticism following a disappointing earnings report that revealed a lack of near-term tenant revenue. The community is sharply divided, with some investors aggressively calling for leadership changes and reporting the firm to the SEC, while others view the current price drop as a strategic buying opportunity in anticipation of future data center power demand.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is seeing heightened trading activity as the company's recent operational updates and offtake agreements drive significant investor interest, leading to strong buying momentum in the stock. The community is actively debating the stock's potential for a breakout, with many discussing the impact of lithium supply-demand dynamics and monitoring insider buying as a key indicator of confidence in future growth.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community leans into its roots as a foundational internet meme, bolstered by the restoration of its original RageBuilder and Ragemaker tools. Enthusiasts are actively rallying around the project as a long-term culture play, emphasizing organic growth and community-driven content production as they target long-term valuation milestones.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending following the TETON-1 study's success in meeting its primary efficacy endpoint for treating idiopathic pulmonary fibrosis, driving investor optimism regarding the company's pipeline expansion. The community is actively discussing the drug's potential market impact, the competitive landscape involving inhaled treprostinil treatments, and broader implications for the company's valuation as it maintains its strong commercial presence.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing intense scrutiny following the release of elegrobart REVEAL-1 phase 3 data, which triggered a significant pre-market stock decline despite meeting primary endpoints. Investors are actively debating the drug's competitive positioning against current standard-of-care treatments, with community sentiment divided between those viewing the pullback as a buying opportunity and skeptics questioning its long-term viability without head-to-head trial data.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors gear up for the upcoming fiscal year-end and 10-K filing, with the community highly focused on QNX revenue growth, backlog expansion, and the impact of the new Alloy Kore platform. Shareholders are actively debating management's guidance and the potential for a long-awaited breakout as they look for concrete signs of sustainable double-digit growth.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air is trending as investors digest the airline's latest quarterly results and guidance, with the market focused on its aggressive growth strategy and integration of Hawaiian Airlines. Community sentiment remains largely bullish, highlighting strong demand, operational efficiency, and a significant share buyback plan that continues to drive positive momentum.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is experiencing high volatility as investors weigh the company's critical role in defense and aerospace supply chainshighlighted by recent Army qualification and major production contractsagainst significant institutional selling pressure and concerns over potential dilution. The community remains deeply divided, with bulls pointing to the company's specialized additive manufacturing technology and long-term potential with prime contractors, while bears focus on high short interest and the ongoing financial challenges facing the company's low-float structure.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific (BSX) is trending following positive data from the Champion-AF clinical trial, which confirmed the safety and efficacy of the Watchman FLX device compared to standard anticoagulants. Community discourse remains highly active, balancing excitement over the company's clinical innovation with skepticism driven by ongoing litigation, recent analyst price target adjustments, and the broader macro-driven rotation within the medtech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


koko55itcom

koko55